[go: up one dir, main page]

CA2677892A1 - Neurogenic compounds - Google Patents

Neurogenic compounds Download PDF

Info

Publication number
CA2677892A1
CA2677892A1 CA002677892A CA2677892A CA2677892A1 CA 2677892 A1 CA2677892 A1 CA 2677892A1 CA 002677892 A CA002677892 A CA 002677892A CA 2677892 A CA2677892 A CA 2677892A CA 2677892 A1 CA2677892 A1 CA 2677892A1
Authority
CA
Canada
Prior art keywords
group
sugar
compound
gallate
gallactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002677892A
Other languages
English (en)
French (fr)
Inventor
John F. Hammerstone, Jr.
Mark A. Kelm
Fred H. Gage
Henriette Van Praag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mars Inc
Salk Institute for Biological Studies
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2677892A1 publication Critical patent/CA2677892A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002677892A 2007-02-14 2008-02-13 Neurogenic compounds Abandoned CA2677892A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90123907P 2007-02-14 2007-02-14
US60/901,239 2007-02-14
PCT/US2008/001914 WO2008147483A2 (en) 2007-02-14 2008-02-13 Neurogenic compounds

Publications (1)

Publication Number Publication Date
CA2677892A1 true CA2677892A1 (en) 2008-12-04

Family

ID=39763345

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002677892A Abandoned CA2677892A1 (en) 2007-02-14 2008-02-13 Neurogenic compounds

Country Status (9)

Country Link
US (1) US20080227829A1 (de)
EP (2) EP2478901A3 (de)
JP (1) JP2010518164A (de)
CN (1) CN101951768A (de)
AU (1) AU2008257437A1 (de)
CA (1) CA2677892A1 (de)
IL (1) IL200383A0 (de)
RU (1) RU2009134137A (de)
WO (1) WO2008147483A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349832B2 (en) * 2009-09-02 2013-01-08 Canthera Therapeutics Compounds and compositions for treating cancer
EP2473506A4 (de) 2009-09-02 2013-03-06 Canthera Therapeutics Inc Verbindungen und verfahren zur behandlung von krebs
US8318737B2 (en) 2009-09-02 2012-11-27 Canthera Therapeutics Inc. Compounds and compositions for treating cancer
WO2011049629A2 (en) 2009-10-22 2011-04-28 Api Genesis, Llc Methods of making and using compositions comprising flavonoids
AU2011318580B2 (en) 2010-10-22 2016-01-07 Technology Investments Lc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US9527860B2 (en) 2011-06-17 2016-12-27 Ludwig Aigner Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders
KR102028625B1 (ko) * 2012-01-17 2019-10-04 산토리 홀딩스 가부시키가이샤 신규 당 전이 효소 유전자 및 그의 사용
WO2016072522A1 (ja) * 2014-11-06 2016-05-12 国立大学法人 長崎大学 新規アルツハイマー病治療薬
JP6207545B2 (ja) * 2015-04-30 2017-10-04 丸大食品株式会社 学習記憶能力増強剤
JP6842093B2 (ja) * 2019-08-20 2021-03-17 丸大食品株式会社 学習記憶能力増強剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317071D0 (en) * 1993-08-17 1993-09-29 Univ Strathclyde Flavonoids
GB9521184D0 (en) * 1995-10-17 1995-12-20 Univ Strathclyde Flavonoids
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
CA2313789A1 (en) * 1998-07-16 2000-01-27 Aaron Tabor Soy formulations and their use for promoting health
AU5759899A (en) * 1998-09-24 2000-04-10 Mitsubishi Chemical Corporation Hydroxyflavone derivatives as tau protein kinase 1 inhibitors
US6451837B1 (en) * 1999-09-01 2002-09-17 Andrius Baskys Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
EP1127572A3 (de) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Verwendung von Flavonen zur Behandlung von Cyclooxygenase-2 ermittelten Krankheiten
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US6472436B1 (en) * 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
JP4633897B2 (ja) * 2000-08-17 2011-02-16 長瀬産業株式会社 神経突起伸長剤
US6733797B1 (en) * 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
WO2002076473A1 (fr) * 2001-03-26 2002-10-03 Academy Of Military Medical Sciences Institute Of Pharmacology And Toxicology Derive de quercetine et son utilisation medicinale
AU2002322233C1 (en) * 2001-07-27 2014-02-13 Aker Biomarine Antarctic As Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
JP4609875B2 (ja) * 2001-07-31 2011-01-12 有限会社大長企画 健康食品
CN101965974A (zh) * 2002-07-24 2011-02-09 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其用途
WO2004037193A2 (en) * 2002-10-22 2004-05-06 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
WO2005020881A2 (en) * 2003-09-01 2005-03-10 Shanghai Comman Pharmaceutical Co. Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases
KR100610562B1 (ko) * 2004-06-28 2006-08-08 재단법인서울대학교산학협력재단 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물
US20060148727A1 (en) * 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
US7442394B2 (en) * 2005-05-02 2008-10-28 University Of South Florida Combined effects of nutrients on proliferation of stem cells
WO2008011538A2 (en) * 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory

Also Published As

Publication number Publication date
RU2009134137A (ru) 2011-03-27
EP2117306A4 (de) 2010-02-10
EP2478901A3 (de) 2012-11-14
WO2008147483A2 (en) 2008-12-04
CN101951768A (zh) 2011-01-19
EP2478901A2 (de) 2012-07-25
AU2008257437A1 (en) 2008-12-04
WO2008147483A3 (en) 2009-02-26
IL200383A0 (en) 2010-04-29
EP2117306A2 (de) 2009-11-18
JP2010518164A (ja) 2010-05-27
US20080227829A1 (en) 2008-09-18
WO2008147483A9 (en) 2009-04-09
WO2008147483A8 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
EP2478901A2 (de) Neurogene Verbindungen
US6335361B1 (en) Method of treating benign forgetfulness
Thomas et al. Choline supplementation following third-trimester-equivalent alcohol exposure attenuates behavioral alterations in rats.
US20230072854A1 (en) Paraxanthine-based bioactive composition and method of use thereof
US7763588B2 (en) Method for increasing cognitive function and neurogenesis
Oliveira et al. Respiratory disturbances in a mouse model of Parkinson's disease
US20230037138A1 (en) Paraxanthine-based caffeine substitute compositions and method of use thereof in slow caffeine metabolizers
AU2017336291A1 (en) Omega 3 fatty acids, no releasing compound and vitamin B12 as neuroprotectant in patients with no dementia
US20130316966A1 (en) Use of albiflorin and metabolites thereof
CN106361738A (zh) 治疗、预防脑白质损伤的医药组合物及其医药用途
Hu et al. Effect of kai xin san on learning and memory in a rat model of paradoxical sleep deprivation
US3819480A (en) Composition of methionine with 2-dimethylaminoethanol
KR101417201B1 (ko) 신경변성 질환을 치료하기 위한 조성물 및 방법
US20240358729A1 (en) Composition containing 2'-fl for ameliorating, preventing or treating diseases caused by reduction of dopamine
KR102037944B1 (ko) 무메푸랄을 포함하는 인지장애 관련 질환의 예방 또는 치료용 조성물
Miller et al. Sensitization of anorexia and locomotion induced by chronic administration of ephedrine in rats
CN115212195B (zh) 苹果酸在制备预防和/或治疗抑郁症的药物中的用途
CN102335338B (zh) 改善帕金森病脑神经递质代谢的中药复方制剂
US20140243400A1 (en) Compositions comprising citric acid and malic acid and methods and uses thereof
JPH02235809A (ja) 嗅覚および味覚の回復におけるレシチンの用途
CN114469967B (zh) 一种苍术苷a及其衍生物在制备抗焦虑和抗抑郁药物上的应用
EP3388061A1 (de) Omega 3 fettensaure, no freilassende verbindungen, vitamin b12 und cholin als neuroschutzhilfsmittel in patienten ohne dementia
US20020077349A1 (en) Method of treating age-related vision impairment
CN115969947B (zh) 达营片在制备治疗焦虑抑郁共病、抑郁症或焦虑症药物中的应用
ES2452916T3 (es) Vicenin 2 y derivados del mismo para utilizar como agente antiespasmódico y/o procinético

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140213